Colgate Palmolive (CL) Common Equity (2009 - 2026)

Colgate Palmolive's Common Equity history runs 18 years deep, the most recent figure standing at $486.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 98.16% year-over-year to $486.0 million in Q1 2026; TTM through Mar 2026 was $486.0 million, a 98.16% decrease from a year earlier, with the FY2025 full-year figure at $365.0 million, up 108.65% from the prior year.
• Common Equity rose to $486.0 million in Q1 2026 per CL's latest filing, from $365.0 million in the prior quarter.
• Across five years, Common Equity topped out at $26.7 billion in Q2 2025 and bottomed at -$25.1 billion in Q4 2022.
• The 5-year median for Common Equity is $450.5 million (2023), against an average of $1.8 billion.
• Biggest YoY gain for Common Equity was 6120.24% in 2024; the steepest drop was 1189.18% in 2024.
• Year by year, Common Equity stood at -$25.1 billion in 2022, then soared by 115.15% to $3.8 billion in 2023, then sank by 210.87% to -$4.2 billion in 2024, then jumped by 108.65% to $365.0 million in 2025, then jumped by 33.15% to $486.0 million in 2026.
• Per Business Quant, the three latest CL Common Equity figures stand at $486.0 million (Q1 2026), $365.0 million (Q4 2025), and $1.2 billion (Q3 2025).